#Japan #cognitive health #Hachioji #Cancer Risk #Metalo Balance

Introduction

In a groundbreaking development for health screenings, the Metalo Balance Test is set to launch at the Iroha Medical Corporation's Tajima Clinic in Hachioji, Tokyo, starting September 15, 2026. This innovative test evaluates the risks of cancer and Mild Cognitive Impairment (MCI) using a mere 6mL of blood, providing a convenient option for residents in the region. Renatech Co., Ltd., based in Isehara, Kanagawa, has developed this test to enhance public health awareness and preventive care.

What is the Metalo Balance Test?

The Metalo Balance Test focuses on analyzing the balance of 17 trace metal elements in the blood, allowing for an objective assessment of an individual's risk for cancer and MCI at the time of testing. With each test providing detailed insights, the assessment helps individuals understand their health status and make informed decisions about their well-being.

Test Features

1. Minimal Sample Required: Only a single blood draw of just 6mL is required for testing, which ensures safety and minimizes discomfort.
2. Comprehensive Cancer Risk Assessment: In one session, it evaluates the risk of cancer across various sites—six types for men, including lung and prostate cancer, and nine for women, which includes breast and cervical cancer.
3. Thorough MCI Evaluation: The test not only focuses on Alzheimer's but also assesses vascular and Lewy body dementia, providing a wide-ranging overview of cognitive health risks.
4. Proven Research Backing: Developed with funding from the Ministry of Economy, Trade, and Industry's Go-Tech initiative, Renatech collaborated with the Kanagawa Prefectural Cancer Center and Chiba Cancer Center, establishing a reliable method recognized in nine countries worldwide, with over 100,000 tests conducted.

How to Take the Test

To participate in the Metalo Balance Test, individuals must pre-register about three weeks in advance due to necessary paperwork. Below is the process:
1. Registration: Interested individuals can register via the website or phone. Test documents will be sent a week prior to the scheduled date.
2. Testing Day: A short, smooth blood draw session lasting about 15 minutes will take place, with payment processed after the test.
3. Results Announcement: Results will be dispatched approximately three weeks post-testing, with a billing statement arriving one week earlier.

Important Pre-Test Guidelines

• - Fasting Required: Participants must refrain from eating or drinking alcohol after 21:00 the night before testing. However, hydration is recommended.
• - Medication Instructions: Over-the-counter medications and supplements should not be taken the day before, while prescribed medications can be taken as usual.

Pricing

This test is offered as a self-paying service, with different options available:

• - Cancer risk assessment: ¥19,800 (tax included)
• - Cognitive risk assessment: ¥19,800 (tax included)
• - Comprehensive package for both assessments: ¥24,200 (tax included)

Eligibility and Restrictions

The Metalo Balance Test is available for:

• - Cancer Risk: Individuals aged 20-80 years
• - Cognitive Risk: Individuals aged 50-80 years

Exclusions: Those who are pregnant, currently undergoing cancer treatment, or experiencing certain health conditions (e.g., kidney dialysis, severe fatigue) cannot take the test.

New Medical Facility Details

• - Start Date: September 15, 2026.
• - Clinic Name: Iroha Medical Corporation, Tajima Clinic
• - Location: 2263-5 Motohachioji-cho, Hachioji, Tokyo 193-0826. Accessibility options are provided, including nearby public transport.

Note: For inquiries related to the test, please contact Renatech directly rather than the clinic.

For more details and to apply for the test, visit Metalo Balance Test or call 0120-785-602 during weekdays.

Company Overview

Renatech Co., Ltd. is dedicated to innovative technology development aimed at early disease risk assessment in the healthcare sector, recognized by governmental initiatives for its contributions to public health and safety. As the demand for early detection and preventive care rises, initiatives like the Metalo Balance Test demonstrate the potential for technological advancements to improve population health.